IDEXX LaboratoriesXTER:IX1 96 Interest Coverage is 46.84 as of Mar. 2026, which is 115% above its 10-year median of 21.76. GuruFocus rates XTER:IX1 with a GF Score™ of 96/100 and a GF Value™ of €559.26. Among 95 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 73.68% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. IDEXX Laboratories's
Operating Income
for the
three
months ended in Mar. 2026 was €314 Mil. IDEXX Laboratories's Interest Expense for the
three
months ended in Mar. 2026 was €-7 Mil.
IDEXX Laboratories's interest coverage for the quarter that ended in Mar. 2026 was 46.84.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for IDEXX Laboratories's Interest Coverage or its related term are showing as below:
XTER:IX1'
s Interest Coverage Range Over the Past 10 Years
Min: 10.93 Med: 21.76 Max: 36.16
Current: 36.12
XTER:IX1's Interest Coverage is ranked better than 73.68% of 95
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.05
vs XTER:IX1: 36.12
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
IDEXX Laboratories Interest Coverage Related Terms
IDEXX Laboratories Interest Coverage Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XTER:IX1 vs A, WAT, NTRA: Interest Coverage Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Interest Coverage distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (XTER:IX1) has a Interest Coverage of 46.84 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on IDEXX Laboratories and its competitors. This is 115% above median its historical median of 21.76. Over the past decade, IDEXX Laboratories' Interest Coverage has ranged from 10.93 to 36.16. According to the industry distribution chart, IDEXX Laboratories ranks #25 out of 95 companies in the Medical Diagnostics & Research industry, placing it in the top 26.3%.
Is IDEXX Laboratories' Interest Coverage too high?
IDEXX Laboratories' current Interest Coverage of 46.84 is 115% above median its 10-year median of 21.76. Over the past 10 years, this metric has ranged from a low of 10.93 to a high of 36.16. The Medical Diagnostics & Research industry median Interest Coverage is 9.05. IDEXX Laboratories' value of 46.84 is 417.6% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #25 out of 95 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, IDEXX Laboratories has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Interest Coverage compare to A and WAT?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #25 out of 95 companies for Interest Coverage. This puts IDEXX Laboratories in the upper half of its industry. The industry median Interest Coverage is 9.05. IDEXX Laboratories' value of 46.84 is 417.6% above this benchmark. Historically, IDEXX Laboratories' own Interest Coverage has ranged from 10.93 to 36.16 over the past decade. While the company's 10-year median is 21.76 vs. the industry median of 9.05, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current Interest Coverage of 46.84 is 417.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current Interest Coverage is 46.84, which is 115% above median its own 10-year median of 21.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
IDEXX Laboratories (XTER:IX1) has a current Interest Coverage of 46.84. The stock's GF Value™ is €559.26, compared to a current price of €488.90 — trading 12.6% below its estimated fair value. The current Interest Coverage is 46.84, which is 115% above median its 10-year median of 21.76 and 417.6% above the Medical Diagnostics & Research industry median of 9.05. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For IDEXX Laboratories (XTER:IX1), the current Interest Coverage is 46.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (XTER:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €488.90 is trading 12.6% below its estimated GF Value™ of €559.26.
Key valuation signals for XTER:IX1:
Interest Coverage: 46.84 (115% above median its 10-year median of 21.76)
GF Value™: €559.26 vs. price of €488.90 (12.6% below fair value)
Industry Position: 417.6% above the Medical Diagnostics & Research median (#25 of 95)
No single metric tells the full story. See the XTER:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for XTER:IX1
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:IX1 has been successfully added to your 
